Therapeutic apheresis in neurological, nephrological and gastrointestinal diseases. (June 2019)

• Record Type: Journal Article
• Authors: Chegini, Azita; Ahmadi Karvigh, Sanaz; Rahbar, Maryam; Sharifi Rayeni, AliReza
• Is Part Of: Transfusion and apheresis science. Volume 58:Number 3(2019)
• Page Start: 266
• Page End: 272
• Publication Date: 2019-06
• Subjects: Blood component removal -- Plasma Exchange -- Plasmapheresis -- Autoimmune diseases of the nervous system -- Kidney diseases -- Gastrointestinal diseases; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2019.04.011
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Therapeutic plasma exchange (TPE) is a process in which plasma containing antibodies, immune complexes, inflammatory moderators, paraproteins and other toxins which are believed to be the cause of disease is removed from a patient. TPE is the first-line treatment (category I, level 1A) in all forms of Acute inflammatory demyelinating polyradiculoneuropathy disease (axonal, demyelinating and miller-fisher variant) as well as in acute myasthenic crisis, chronic inflammatory demyelinating polyradiculoneuropathy and Paraproteinemic neuropathies (category I, level 1B). Moreover, TPE in kidney diseases, for instance: desensitization in renal transplantation(ABO compatible) (living donor)and desensitization in deceased donor, desensitization in renal transplantation(ABO incompatible) (living donor), thrombotic microangiopathy complement Mediated (Factor H autoantibodies), Focal segmental glomerulosclerosis(recurrent in transplanted kidney), ANCA-associated rapidly progressive glomerulonephritis(Dialysis dependence, DAH), Anti-Glomerular basement membrane disease Goodpasture's syndrome)(DAH, Dialysis-independence, ) has been utilized as an initial treatment. (category I) TPE has been used as the key therapeutic modality to reduce anti-A or anti-B antibody titers in the liver peri-transplant period with the goal of preventing rejection and facilitating graft survival. Also, plasma exchange is the first-line therapy in Wilson's disease (category I, level1C).